Moderna will receive up to $54.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of the pharmaceutical company's mRNA-based pandemic flu vaccine.
Following President Donald Trump's announcement of artificial intelligence (AI) data centers across the United States, Oracle CEO Larry Ellison said the project may be used to develop mRNA vaccines.
Respiratory Syncytial Virus (RSV) vaccines from GSK and Pfizer will carry warnings for an increased risk of Guillain-Barré syndrome (GBS), the U.S. Food Drug Administration (FDA) said.
